Nightingale Health Plc
Company release
20 September 2024 at 1:45 p.m. (EEST)

Nightingale Health Plc’s (“Nightingale Health”) Board of Directors has resolved to amend CEO’s stock option program by issuing additional 1,000,000 stock option rights to the CEO.

The right to subscribe for shares with the new stock option rights is earned based on reaching the market capitalization of 1,500 million.

Each option right entitles the CEO to subscribe for one Series B share. The subscription price of each share is EUR 6.75 per share.

The Board of Directors has on 3 March 2021 resolved on the CEO’s stock option program by issuing 2,000,000 stock option rights of which 1,000,000 can be subscribed for Series B shares based on reaching market capitalization of EUR 500 million (first vesting event) and 1,000,000 based on reaching market capitalization of 1,000 million (second vesting event). With the amendment the total number of stock option rights based on the CEO's stock option program is 3,000,000 stock option rights. The market capitalizations are calculated based on the volume weighted average price.

The purpose of the stock option program is to bind the option holder to the economic growth of Nightingale Health and to the development of Nightingale Health’s market capitalization as well as create a long-term relationship between Nightingale Health and the option holder which benefits the company both economically and operationally.

The decision regarding the new stock options was done based on the authorization granted by the Extraordinary General Meeting held on 18 February 2021.

The share subscription period for the stock option programs ends on 31 December 2031.

For further information, please contact:

Teemu Suna, CEO
ir@nightingalehealth.com

Certified advisor:

Oaklins Merasco Ltd, tel. +358 9 6129 670

About Nightingale Health

Nightingale Health’s mission is to build sustainable healthcare and reduce health inequalities. Nightingale Health has developed the world’s most advanced health check that provides risk detection for multiple chronic diseases from a single blood sample. Nightingale’s Health Check can be scaled to entire populations at a low cost, and it can replace many of the current clinical risk assessments. Detecting disease risks on a population level allows for the effective targeting and tracking of health interventions, and better prevention of the onset of chronic diseases. With every sample we help to create a healthier world.

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 34 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 600 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com/